Author: Eunoia Consulting Co. | Published: September 21, 2026
A practical, source-backed review of healthcare AI vendor data use, retention, export, continuity and exit questions before an agreement is signed.
A healthcare AI agreement should do more than name a product and a price. Before signature, the buyer should be able to explain what information enters the service, who may handle it, how it may be used, what evidence supports the service, how access is maintained, and what happens if the relationship changes or ends.
That is not a call for every organisation to use the same contract language. HIPAA obligations depend on the relationship and on the information handled. Commercial protections such as export formats, transition assistance, audit rights, service levels, model-improvement limits, or a deletion certificate are negotiated terms. This article offers a structured question set for internal review with procurement, privacy, security, clinical, operations, technology, and qualified legal advisers. It is not legal advice and it does not determine whether a particular vendor or deployment is compliant.
The term “AI vendor” does not answer the core contractual question: what does the vendor actually create, receive, maintain, transmit, derive, or disclose? A useful review begins with a data map rather than a product category.
For each workflow, identify the information that may enter the service. This can include patient or member information, clinician prompts, attachments, images, transcripts, account identifiers, metadata, support tickets, audit records, outputs, telemetry, derived data, and de-identified information. Then identify every party that may handle it: the application vendor, model provider, hosting provider, integration partner, subprocessor, implementation partner, and support function.
This matters because the HIPAA business-associate analysis is relationship-specific. HHS explains that a cloud service provider that creates, receives, maintains, or transmits electronic protected health information (ePHI) for a covered entity or business associate is a business associate. That may include storage of encrypted ePHI even when the provider does not hold the decryption key. [1] [2] The same guidance distinguishes persistent storage or processing from transmission-only conduit arrangements and notes that properly de-identified information is different from PHI. [1]
The practical question is not “Does the vendor call itself HIPAA-ready?” It is “What data flows exist, which party performs which function, and which contractual and operational controls fit those facts?”
Where the relationship requires a business associate agreement (BAA), the agreement has defined HIPAA functions. The Privacy Rule requires qualifying BAAs to address permitted and required uses and disclosures, safeguards, certain incident reporting, qualifying subcontractors, and support for the covered entity’s duties regarding access, amendment, and accounting of disclosures. It also requires provisions concerning relevant HHS access, material breach, and PHI disposition at termination. [3]
The Security Rule separately requires satisfactory assurances that a business associate will appropriately safeguard ePHI. [4] Those requirements are important, but a BAA is not a product certification. It does not by itself establish that a specific model, workflow, configuration, clinical use, or security programme is appropriate.
HHS describes service-level agreements as a way to state business expectations and identifies availability, reliability, backup and recovery, post-termination data return, security responsibility, and limits on use, retention, and disclosure as topics an SLA can address. [1] These are useful review areas. They are not a universal HHS checklist with prescribed uptime percentages, recovery times, incident-notice deadlines, or export formats.
A sound internal approach separates three layers:
Keeping these layers separate helps teams avoid a common mistake: presenting a preferred commercial term as if it were automatically a HIPAA or NIST requirement.
Healthcare organisations should seek a precise answer to how customer information will be used. The agreement and supporting documentation should make it possible to distinguish inputs, prompts, outputs, logs, backups, support data, telemetry, derived data, and de-identified data. The buyer should then ask whether each category may be used only to provide the contracted service or may also be used for model improvement, training, evaluation, abuse monitoring, aggregation, or another purpose.
The purpose is not to assume that every secondary use is prohibited. It is to make the data-use boundary visible, reviewed, and intentional. If a vendor proposes a secondary use, the organisation should understand the applicable data category, the parties involved, the approvals and controls, retention, access, and how the proposed use aligns with its own policies and obligations.
NIST’s AI Risk Management Framework is voluntary guidance, not a healthcare AI contract template or a certification. [5] Its Generative AI Profile nevertheless provides a useful risk-management lens: third-party data, software, and hardware can create risks that require defined policies, due diligence, and contingency processes. [6] That supports asking a vendor to explain its data-use terms and third-party dependencies. It does not make NIST the owner of customer data or authorise vendor training on customer information.
The original contract can be undermined if a material part of the service changes without a review path. Ask for a current description of hosting, model, and subprocessor dependencies. Establish how the organisation learns about a material change to the model, data flow, hosting location, integration, security posture, or support arrangement.
NIST’s guidance identifies procurement due diligence, software bills of materials, service-level agreements, and independent assurance materials as options that may support third-party transparency and risk management. [6] A proportionate evidence request might include a security questionnaire, an independent report, a summary of relevant testing, an SBOM where appropriate, incident records, or an explanation of service dependencies. The appropriate package depends on the use case and risk; no one document proves that a system is compliant, safe, accurate, or suitable.
For healthcare teams, the more useful question is: What evidence would allow the accountable owner to understand a material change and make a decision? That can include a change notice, a description of affected workflows, data-use implications, validation and monitoring information, a rollback or disablement path, and an owner for follow-up.
Access terms deserve attention before a relationship is under stress. HHS states that a business associate generally may not block or terminate a covered entity’s access to PHI it maintains on the entity’s behalf to resolve a payment dispute. HHS describes ePHI in this context as needing to be accessible and usable on demand. [7]
That does not mean every access question has the same answer. The organisation should review suspension rights, fees, insolvency, outages, maintenance windows, dispute provisions, and continuity safeguards in the actual agreement. It should also ensure that the BAA, SLA, security terms, and operating procedures do not contradict one another.
A reasonable continuity discussion can cover:
These questions do not replace incident response or business continuity planning. They make the contractual and operational hand-off visible before it becomes urgent.
Termination provisions are often reviewed late, after a vendor has already become embedded in clinical or operating workflows. A stronger approach treats exit planning as part of implementation readiness.
For a qualifying BAA, HIPAA requires return or destruction, if feasible, of PHI that the business associate still maintains in any form and that it received from, or created or received on behalf of, the covered entity. No copies may be retained. If return or destruction is infeasible, BAA protections must continue and further uses and disclosures must be limited to the purpose that makes disposition infeasible. [3]
HHS gives retention required by another law as an example of infeasibility and states that HIPAA generally does not require a cloud service provider to retain ePHI after it has finished providing services. [8] Commercial preference, technical inconvenience, a backup label, or a payment dispute should not be treated as an automatic answer to the feasibility question.
HHS also says that, when a BAA calls for return of ePHI, the format should be reasonable in light of the agreement so the information remains accessible and usable. [7] That supports a careful review of usability. It does not create a universal HIPAA requirement for a particular application programming interface, file type, migration period, conversion service, or deletion certificate.
A negotiation-focused exit question set can therefore ask:
HHS provides sample BAA provisions, but it states that they are optional, may be adapted, and alone may not establish a binding contract under state law. [9] Similarly, HHS says HIPAA does not expressly require a cloud service provider to provide security-practice documentation or audit access, although customers may seek additional assurances through their risk analysis and negotiations. [1]
These boundaries are useful. They let a buyer ask for meaningful evidence without claiming that HHS requires a particular report or audit right. They also encourage leaders to connect the contract to the organisation’s own governance process: name the accountable owner, identify the records that matter, define evidence and decision thresholds, and document exceptions that remain open.
Before signature, bring the draft agreement, BAA where applicable, service description, security materials, subprocessor information, and implementation plan into one focused review. Map the data flow. Identify the clinical and operational dependency. Separate legal baselines from negotiated protections. Then record the unresolved questions, the requested evidence, the owner, and the decision needed before the service moves forward.
Eunoia Consulting Co. helps healthcare organisations translate AI vendor questions into an accountable review process across governance, data use, operational readiness, and third-party risk. To discuss a focused, human-led Healthcare AI Data-Use and Exit Question Set for one proposed workflow, book a strategy conversation or explore AI governance advisory. This is advisory support for internal decision readiness, not legal sign-off.
This article was produced by the Eunoia Consulting Co. Editorial Team. Eunoia Consulting Co. specialises in AI governance, healthcare operations, and data strategy for healthcare and veterinary organisations.
[1] HHS OCR: Guidance on HIPAA & Cloud Computing
[2] 45 CFR § 160.103 — Definitions
[3] 45 CFR § 164.504 — Uses and Disclosures: Organizational Requirements
[4] 45 CFR § 164.314 — Organizational Requirements
[5] NIST AI 100-1: Artificial Intelligence Risk Management Framework
[6] NIST AI 600-1: Generative AI Profile
[7] HHS OCR FAQ: Business Associate Access to PHI